(Q48439989)

English

Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.

scientific article published on 11 July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

Alzheimer's disease

0 references

3

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

Giuseppe Bellelli

5

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

José Luis Molinuevo

6

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

Jeffrey L. Cummings

1

object named as

Jeffrey Cummings

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

author name string

Lutz Froelich

2

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

Serge Bakchine

4

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

Reto W Kressig

7

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

Pamela Downs

8

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

Angelika Caputo

9

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

Christine Strohmaier

10

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

publication date

11 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

Dementia and Geriatric Cognitive Disorders

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

33

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

5

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

341-353

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

Predicting caregiver burden from daily functional abilities of patients with mild dementia

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Prediction of institutionalisation in dementia. A systematic review

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Treatment options in Alzheimer's disease: maximizing benefit, managing expectations

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Effects of Two-Year Treatment with the Cholinesterase Inhibitor Rivastigmine on Behavioural Symptoms in Alzheimer’s Disease

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Pharmacokinetic rationale for the rivastigmine patch

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Relationships between parts A and B of the Trail Making Test.

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale.

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Impact of rivastigmine on caregiver burden associated with Alzheimer's disease in both informal care and nursing home settings

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1159%2F000340056

21 January 2018

Identifiers

10.1159/000340056

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

release_yjmdea7shrgn7iiomkolozohba

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22796905

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48439989&oldid=1289541332"